Regulatory Novartis secures pair of regulatory wins for skin disease and malaria treatments Pharmaceutical TechnologyNovartis' Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaceutical Technology Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New NIHR-funded TRC for Parkinson’s diseaseNext: Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
